Biotech Stock

Will Zerenex Help Keryx

May 14, 2012

Keryx Biopharmaceuticals  moved north as they received positive result from Japan on Zerenex. Even after the late-week run of KERX shares, this stock still may have significant room left to move to the upside, especially during the lead-in to Zerenex Phase III results, which are due out later this year. Investers should note that Keryx [...]

Read the full article →

Bright Future for Geron

September 28, 2011

A startup Biotech company is evaluated primarily by products in the pipeline. GERN’s current well publicized trial is dealing with using stem cells to treat patients with spinal cord injuries so they can regain mobility. Don’t get me wrong, if GERN is successful with their stem cell technology it will be a game changer for [...]

Read the full article →

ImmunoGen Riding on Phase 2 Trial Results

April 10, 2011

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company focused on developing cancer drugs, saw its stock climb 22 percent on news that its potential therapy for breast cancer achieved positive phase 2 trial results. The results showed that that this new experimental therapy could potentially be more effective than a combination of Herceptin and chemotherapy, which [...]

Read the full article →

SOMX time to Buy or Sell?

March 29, 2010

Now Somaxon Pharmaceuticals, Inc’s Silenor is approved by the FDA and SOMX is planning to market the medicine. For that they issued 6million shares for a total of $49.5 million, making the total outstanding shares to 30million.  Currently SOMX is trading at $8.8 . Now is it the right price for the share? If you [...]

Read the full article →

Biotech Stocks Waiting FDA Approval

February 18, 2010

One sure way to gain in stock market is to bet on Biotech Stocks waiting on FDA Approval. Selling out just before FDA approval is a sure way of generating good profit.  Most of them sell out a portion just before the FDA decision. In case the decision goes against, still they are not in [...]

Read the full article →